SCORE

33

ATXI: Avenue Therapeutics is a Sell


The current rating for ATXI is 33, which is 52% below its historic median rating of 50. This indicates higher risk than normal.


The rating is currently showing a lower than normal reading, suggesting risk levels could be higher than normal and additional caution is advised.